View Older Stories View More Recent Stories

Dec 11, 2017 05:44AM Incyte (INCY) Reports our-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients with Polycythemia Vera
Dec 10, 2017 07:31AM Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera
Nov 15, 2017 07:30AM Incyte (INCY) Begins Pivotal Clinical Trial of Ruxolitinib for Treatment of Essential Thrombocythemia
Nov 15, 2017 07:30AM Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia
Nov 5, 2017 09:00AM ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
Nov 1, 2017 11:14AM Incyte (INCY) Says More Than 30 Abstracts Highlighting Data from its Portfolio Accepted for Presentation at ASH
Nov 1, 2017 11:14AM More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting
Oct 31, 2017 07:00AM Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs
Oct 31, 2017 06:20AM Incyte (INCY), AstraZeneca (AZN) Expand Clinical Trial Collaboration in Early Lung Cancer
Oct 31, 2017 03:00AM Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer
Oct 30, 2017 04:47PM Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board
Oct 30, 2017 04:30PM Incyte Names New Member to Its Board of Directors
Oct 25, 2017 06:49AM Incyte (INCY) and MacroGenics (MGNX) Enter Pact on Anti-PD-1 Monoclonal Antibody MGA012
Oct 25, 2017 06:45AM Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
Oct 24, 2017 08:00AM Incyte to Present at Upcoming Investor Conference
Oct 12, 2017 04:10PM Incyte to Report Third Quarter Financial Results
Oct 6, 2017 09:00AM Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware
Sep 18, 2017 10:00AM Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell
Sep 14, 2017 09:02AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Announces Baricitinib Meets Primary Endpoint in Phase 2 Study
Sep 14, 2017 09:00AM Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017 05:48AM Incyte (INCY) Reports Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with Merck (MRK) KEYTRUDA (pembrolizumab)
Sep 9, 2017 08:49AM Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Sep 9, 2017 08:45AM Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melano
Sep 1, 2017 09:00AM Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
Aug 31, 2017 05:47AM Incyte (INCY) Announces New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Aug 30, 2017 07:05PM New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Aug 30, 2017 06:46AM Eli Lilly (LLY) Plans to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Aug 30, 2017 06:45AM Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Aug 10, 2017 08:45AM Forbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year
Aug 1, 2017 07:00AM Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
Jul 25, 2017 06:18AM Lilly (LLY), Incyte (INCY) Announce Resubmission of NDA for Baricitinib Will Be Delayed Beyond 2017
Jul 25, 2017 06:15AM Lilly and Incyte Provide Update on Baricitinib
Jul 20, 2017 07:34AM Incyte (INCY) Says First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute GVHD
Jul 20, 2017 07:30AM Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease
Jul 11, 2017 08:00AM Incyte to Report Second Quarter Financial Results
Jul 3, 2017 08:00AM Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis
Jun 16, 2017 06:18AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Present New Safety & Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis
Jun 16, 2017 04:15AM New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Jun 13, 2017 06:01PM Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)
Jun 7, 2017 04:15PM Incyte to Present at Upcoming Investor Conferences
Jun 5, 2017 08:00AM Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017
Jun 5, 2017 07:35AM Incyte (INCY), Bristol-Myers Squibb (BMY) Announce Trial Data for Combination of Epacadostat and Opdivo Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
Jun 5, 2017 07:30AM Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
Jun 5, 2017 07:05AM Incyte (INCY), Merck (MRK) Provide Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA
Jun 5, 2017 07:00AM Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types
Jun 5, 2017 05:52AM Incyte (INCY) Updates Data on Combination of Epacadostat plus Keytruda (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer
Jun 3, 2017 09:00AM Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Jun 3, 2017 09:00AM Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
May 22, 2017 04:15PM Incyte to Present at Upcoming Investor Conferences
May 17, 2017 05:15PM Incyte (INCY) Says First Data from Combination of Epacadostat with Opdivo Will Be Highlighted at ASCO
View More Recent Stories View Older Stories